UCB: 2017 financial outlook raised, but shares unresponsive.
(CercleFinance.com) - UCB has raised its financial outlook for 2017 after the Belgian pharmaceutical group delivered a "good" nine-month performance.
The company now expects full-year revenue of between 4.4 billion and 4.5 billion euros this year, versus a previous forecast of 4.35 billion - 4.45 billion euros, with core EPS expected between 4.10 and 4.50 euros.
Over the first nine months of 2017, revenue increased by 9% to 3.3 billion euros, with main products like the drug Cimzia for Crohn's disease growing by 15% alone.
Despite this, UCB shares were down 0.4% at 59.9 euros on Euronext Brussels this morning.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The company now expects full-year revenue of between 4.4 billion and 4.5 billion euros this year, versus a previous forecast of 4.35 billion - 4.45 billion euros, with core EPS expected between 4.10 and 4.50 euros.
Over the first nine months of 2017, revenue increased by 9% to 3.3 billion euros, with main products like the drug Cimzia for Crohn's disease growing by 15% alone.
Despite this, UCB shares were down 0.4% at 59.9 euros on Euronext Brussels this morning.
Copyright (c) 2017 CercleFinance.com. All rights reserved.